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CONCLUSIONS: In the two path analytic models evalu-
ated, only patient compliance had a significant direct ef-
fect on PCS. Re-specification of the models is needed.
DECISION ANALYTIC MODELING
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Formulary decisions are often based upon the safety, effi-
cacy, and projected costs of medications. Models used to
predict costs are rarely assessed to determine their predic-
tive ability.
OBJECTIVE: The purpose of this study was to assess the
ability of a decision analytic deterministic model and a re-
gression analytic stochastic model to predict the diabetes-
specific costs incurred during the 12 months after met-
formin was added to an HMO formulary. The ability of
the stochastic model to predict total healthcare costs was
also assessed.
METHODS: The deterministic model, a decision tree,
was constructed within an equilibrium framework using
literature-based probabilities and internal costs to predict
diabetes-specific costs. A regression model was con-
structed using medical and pharmacy claims data to pre-
dict diabetes-specific cost and total healthcare costs.
RESULTS: The total diabetes-specific cost estimate pre-
dicted by the decision analytic model came within 5% of ac-
tual costs. The model underestimated the diabetes-specific
medical costs and overestimated the diabetes-specific phar-
macy costs. The diabetes-specific regression model pro-
duced an estimate that was within 18% of the actual costs.
The total healthcare cost model estimate was within 7% of
the actual costs. The total and diabetes-related medical cost
estimates were within 6% and 46% of the actual costs re-
spectively. The total and diabetes-specific pharmacy costs
were within 20% and 49% of the actual costs, respectively.
CONCLUSION: Further research is needed to refine model
construction techniques. A decision tree constructed with
internal data should be used to predict disease-specific costs
when only medical and pharmacy claims data from the pre-
vious year are available, and a regression model should be
used to predict total healthcare costs.
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In response to mounting pressures to improve stroke pro-
phylaxis for patients with atrial fibrillation, many hospi-
tals and healthcare systems have opened specialty antico-
agulation clinics.
OBJECTIVE: The purpose of this study was to determine
the cost-effectiveness of stroke prophylaxis from a hospi-
tal system perspective.
METHODS: We have developed a decision model repre-
senting several options for stroke prophylaxis. Simulated
patients could receive warfarin through either an anticoag-
ulation clinic or their family physician, aspirin, or no ther-
apy. Possible events were thromboembolic stroke, hemor-
rhagic stroke, hemorrhage requiring hospitalization (major
hemorrhage), or hemorrhage requiring a clinic visit and/or
warfarin dose adjustment (minor hemorrhage). Three dif-
ferent scenarios of stroke prophylaxis are presented: 1) a
healthcare system with an anticoagulation clinic; 2) a sys-
tem which maximizes anticoagulation with warfarin via
the family physician; and 3) a system which maximizes an-
ticoagulation but utilizes anticoagulation clinics to a larger
extent.
RESULTS: Option 1 was the least costly and effective
strategy with a 10-year average cost of $6327/patient
treated and a life expectancy of 7.728 years. The values
for 2 and 3 were $6549 and 7.735 life-years, and $6443
and 7.761 life-years, respectively. The incremental cost-
effectiveness was $34,339/life-year saved for 2 versus 1
and $4013/life-year saved for option 3 versus 1. Option 3
was dominant over 2. These results were sensitive to the
cost per clinic or office visit and the rate of occurrence of
major hemorrhage.
CONCLUSION: Increasing warfarin utilization is cost-
effective from a healthcare system’s perspective. Antico-
agulation clinics appear to be the best method for achiev-
ing this goal.
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Decision analytic software is commonly used to estimate
long-term costs or effects of treatment by using Markov
models. Monte Carlo simulation is used to estimate con-
fidence limits (CL) for costs or effects in decision models.
Exact cost or effects may be calculated by matrix inver-
sion. CL for costs and effects may be calculated from ma-
trix inversion by using distributions for each transition
probability.
OBJECTIVES: The objective of this study was to validate
decision analytic software by comparing the bias in deci-
sion analytic CL and matrix CL.
